Incyte Corp.
INCY · NASDAQ-GS
INCY · NASDAQ-GS
Incyte is a biopharmaceutical company, according to the supplied sector classification and stock-analysis coverage. The evidence does not identify its products, operating segments, geographic mix, revenue contribution by segment, customer groups, or commercial distribution model, so those details cannot be stated reliably. The company reports $5.1 billion of FY2025 revenue and $1.3 billion of net income, compared with $4.2 billion of revenue and approximately zero net income in FY2024. Its current scale is therefore established by those reported financial figures, but the supplied material does not describe how revenue is divided among medicines, collaborations, or other sources.
